应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
EXEL 伊克力西斯
未开盘 07-24 16:00:00 EDT
22.35
-0.11
-0.49%
盘后
22.35
+0.00
0.00%
17:11 EDT
最高
22.55
最低
22.20
成交量
100.15万
今开
22.39
昨收
22.46
日振幅
1.56%
总市值
65.10亿
流通市值
57.03亿
总股本
2.91亿
成交额
2,241万
换手率
0.39%
流通股本
2.55亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
伊克力西斯2024财年第一财季实现净利润37.32百万美元,同比减少6.77%
自选股智能写手 · 05-05
伊克力西斯2024财年第一财季实现净利润37.32百万美元,同比减少6.77%
HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价28.00美元。
智通财经 · 05-04
HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价28.00美元。
伊克力西斯盘中异动 股价大跌5.07%报22.48美元
自选股智能写手 · 04-11
伊克力西斯盘中异动 股价大跌5.07%报22.48美元
摩根大通证券公司:重申Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价27.00美元。
智通财经 · 04-10
摩根大通证券公司:重申Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价27.00美元。
伊克力西斯盘中异动 大幅上涨5.00%报21.75美元
自选股智能写手 · 02-23
伊克力西斯盘中异动 大幅上涨5.00%报21.75美元
伊克力西斯2023财年实现净利润2.08亿美元,同比增加14.29%
自选股智能写手 · 02-07
伊克力西斯2023财年实现净利润2.08亿美元,同比增加14.29%
伊克力西斯盘中异动 早盘股价大跌5.27%报20.68美元
自选股智能写手 · 02-07
伊克力西斯盘中异动 早盘股价大跌5.27%报20.68美元
加载更多
公司概况
公司名称:
伊克力西斯
所属市场:
NASDAQ
上市日期:
--
主营业务:
Exelixis, Inc.是一家生物科技公司,致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司,并于2000年2月改为Exelixis股份有限公司。公司的资源、研发、生产专注于COMETRIQ(卡博替尼胶囊,公司全资的多靶点受体酪氨酸激酶抑制剂)。公司目标是将COMETRIQ发展成一项主要的特许肿瘤经营产品,认为COMETRIQ治疗恶化、转移的MTC的批准给实现该目标、树立商业地位提供了一个机会。
发行价格:
--
{"stockData":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"伊克力西斯","latestPrice":22.35,"timestamp":1721851200000,"preClose":22.46,"halted":0,"volume":1001469,"hourTrading":{"tag":"盘后","latestPrice":22.35,"preClose":22.35,"latestTime":"17:11 EDT","volume":93521,"amount":2090182.55,"timestamp":1721855465314},"delay":0,"floatShares":255180448,"shares":291292704,"eps":0.652788,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.11,"latestTime":"07-24 16:00:00 EDT","open":22.39,"high":22.55,"low":22.2,"amount":22405003.672191,"amplitude":0.015583,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.652788,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721894400000},"adr":0,"listingDate":955425600000,"adjPreClose":22.46,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":22.35,"preClose":22.35,"latestTime":"17:11 EDT","volume":93521,"amount":2090182.55,"timestamp":1721855465314},"volumeRatio":0.7709982068014078,"impliedVol":0.6751,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/EXEL","defaultTab":"news","newsList":[{"id":"2433114723","title":"伊克力西斯2024财年第一财季实现净利润37.32百万美元,同比减少6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433114723","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433114723?lang=zh_cn&edition=full","pubTime":"2024-05-05 00:25","pubTimestamp":1714839950,"startTime":"0","endTime":"0","summary":"3月31日,伊克力西斯公布财报,公告显示公司2024财年第一财季净利润为37.32百万美元,同比减少6.77%;其中营业收入为4.25亿美元,同比增加3.91%,每股基本收益为0.12美元。从资产负债表来看,伊克力西斯总负债6.76亿美元,其中短期债务0.00美元,资产负债比为4.15,流动比率为3.47。机构评级:截至2024年3月31日,当前有20家机构对伊克力西斯目标价做出预测,其中目标均价为26.73美元,其中最低目标价为17.00美元,最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050500255787d1ff45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050500255787d1ff45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"2432397701","title":"HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价28.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432397701","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432397701?lang=zh_cn&edition=full","pubTime":"2024-05-04 04:15","pubTimestamp":1714767314,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价28.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405040415188b7149f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405040415188b7149f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"2426265367","title":"伊克力西斯盘中异动 股价大跌5.07%报22.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426265367","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426265367?lang=zh_cn&edition=full","pubTime":"2024-04-11 22:16","pubTimestamp":1712844966,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日22时16分,伊克力西斯股票出现异动,股价急速跳水5.07%。截至发稿,该股报22.48美元/股,成交量49.46万股,换手率0.16%,振幅3.74%。最近的财报数据显示,该股实现营业收入18.30亿美元,净利润2.08亿美元,每股收益0.65美元,毛利17.58亿美元,市盈率34.62倍。伊克力西斯股票所在的生物技术行业中,整体跌幅为1.08%。该信息摘要如下:摩根大通证券公司:重申Exelixis评级,由优于大市调整至优于大市评级, 目标价27.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411221607861e4ff3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411221607861e4ff3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2426852411","title":"摩根大通证券公司:重申Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价27.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426852411","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426852411?lang=zh_cn&edition=full","pubTime":"2024-04-10 23:14","pubTimestamp":1712762099,"startTime":"0","endTime":"0","summary":"摩根大通证券公司:重申Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价27.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102315038b0ae805&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102315038b0ae805&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"2413933087","title":"伊克力西斯盘中异动 大幅上涨5.00%报21.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413933087","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413933087?lang=zh_cn&edition=full","pubTime":"2024-02-23 23:47","pubTimestamp":1708703269,"startTime":"0","endTime":"0","summary":"北京时间2024年02月23日23时47分,伊克力西斯股票出现波动,股价快速拉升5.00%。伊克力西斯股票所在的生物技术行业中,整体涨幅为0.87%。消息层面,截至23时47分,伊克力西斯股票正面舆情新闻比例100%。《伊克力西斯董事增持19万股普通股股份,价值约393.27万美元》资讯为影响伊克力西斯的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240223234749861d7f20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240223234749861d7f20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0},{"id":"2409918273","title":"伊克力西斯2023财年实现净利润2.08亿美元,同比增加14.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2409918273","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409918273?lang=zh_cn&edition=full","pubTime":"2024-02-07 23:27","pubTimestamp":1707319634,"startTime":"0","endTime":"0","summary":"12月31日,伊克力西斯公布财报,公告显示公司2023财年净利润为2.08亿美元,同比增加14.29%;其中营业收入为18.30亿美元,同比增加13.59%,每股基本收益为0.65美元。从资产负债表来看,伊克力西斯总负债7.32亿美元,其中短期债务25.72百万美元,资产负债比为4.10,流动比率为3.35。机构评级:截至2023年12月31日,当前有19家机构对伊克力西斯目标价做出预测,其中目标均价为26.79美元,其中最低目标价为18.00美元,最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020723271881763e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020723271881763e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"2409227686","title":"伊克力西斯盘中异动 早盘股价大跌5.27%报20.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409227686","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409227686?lang=zh_cn&edition=full","pubTime":"2024-02-07 22:30","pubTimestamp":1707316242,"startTime":"0","endTime":"0","summary":"北京时间2024年02月07日22时30分,伊克力西斯股票出现波动,股价大幅跳水5.27%。截至发稿,该股报20.68美元/股,成交量5.0077万股,换手率0.02%,振幅2.59%。最近的财报数据显示,该股实现营业收入18.30亿美元,净利润2.08亿美元,每股收益0.65美元,毛利17.58亿美元,市盈率31.82倍。机构评级方面,在所有20家参与评级的机构中,80%的券商给予买入建议,15%的券商给予持有建议,5%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中,整体跌幅为0.45%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020722304287e6ed7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020722304287e6ed7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exelixis.com","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.0013},{"period":"3month","weight":-0.0501},{"period":"6month","weight":0.0104},{"period":"1year","weight":0.1305},{"period":"ytd","weight":-0.0684}],"compareEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.075},{"period":"6month","weight":0.1104},{"period":"1year","weight":0.1884},{"period":"ytd","weight":0.1387}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Exelixis, Inc.是一家生物科技公司,致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司,并于2000年2月改为Exelixis股份有限公司。公司的资源、研发、生产专注于COMETRIQ(卡博替尼胶囊,公司全资的多靶点受体酪氨酸激酶抑制剂)。公司目标是将COMETRIQ发展成一项主要的特许肿瘤经营产品,认为COMETRIQ治疗恶化、转移的MTC的批准给实现该目标、树立商业地位提供了一个机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.541667,"avgChangeRate":0.018713},{"month":2,"riseRate":0.458333,"avgChangeRate":0.015199},{"month":3,"riseRate":0.541667,"avgChangeRate":-0.009275},{"month":4,"riseRate":0.541667,"avgChangeRate":0.053269},{"month":5,"riseRate":0.44,"avgChangeRate":-0.000424},{"month":6,"riseRate":0.56,"avgChangeRate":0.026357},{"month":7,"riseRate":0.52,"avgChangeRate":0.049111},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.016155},{"month":9,"riseRate":0.458333,"avgChangeRate":-0.044733},{"month":10,"riseRate":0.541667,"avgChangeRate":-0.015438},{"month":11,"riseRate":0.583333,"avgChangeRate":0.058116},{"month":12,"riseRate":0.666667,"avgChangeRate":0.060039}],"exchange":"NASDAQ","name":"伊克力西斯","nameEN":"Exelixis"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伊克力西斯,EXEL,伊克力西斯股票,伊克力西斯股票老虎,伊克力西斯股票老虎国际,伊克力西斯行情,伊克力西斯股票行情,伊克力西斯股价,伊克力西斯股市,伊克力西斯股票价格,伊克力西斯股票交易,伊克力西斯股票购买,伊克力西斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}